PUBLICATION WATCH An Interactive Experience EXAMPLE: Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults Would you like more information? Arrange a quick call to find out more Book now
